GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Aurobindo Pharma AUROPHARMA.NS · INR

Health Care · NSE · 🇮🇳 India

Compare

1,855.30

+3.07%

Close of 9 Nov 2026, in INR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in INR, from our data supplier.

FY2026

Revenue

₹336.53bn

FY2017FY2026

Net income

₹35.05bn

FY2017FY2026

Free cash flow

₹28.27bn

FY2017FY2026

Shareholders' equity

₹378.91bn

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue₹336.53bn₹317.24bn₹290.02bn₹248.55bn₹234.55bn₹247.75bn₹230.99bn₹195.64bn₹164.63bn₹149.33bn
Research and development₹1.55bn₹16.92bn₹15.22bn₹14.53bn₹16.25bn₹15.24bn₹9.62bn₹8.68bn₹6.70bn₹5.45bn
Operating income₹54.96bn₹55.24bn₹46.70bn₹81.05bn₹78.06bn₹94.03bn₹87.75bn₹69.88bn₹66.24bn₹60.86bn
Net income₹35.05bn₹34.86bn₹31.73bn₹19.27bn₹26.48bn₹53.35bn₹28.45bn₹23.65bn₹24.23bn₹23.02bn
Diluted earnings per share60.6260.0254.6233.0245.1791.0448.5640.3641.3439.30

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets₹585.02bn₹497.85bn₹450.72bn₹398.90bn₹339.22bn₹338.54bn₹289.28bn₹264.54bn₹211.01bn₹162.49bn
Cash and short-term investments₹106.18bn₹82.36bn₹63.25bn₹62.24bn₹45.58bn₹56.21bn₹28.42bn₹19.29bn₹12.41bn₹5.12bn
Total liabilities₹206.19bn₹171.38bn₹152.21bn₹130.38bn₹93.48bn₹119.25bn₹121.03bn₹125.62bn₹94.19bn₹68.75bn
Debt—₹82.63bn₹66.48bn₹52.86bn₹30.11bn₹53.92bn₹59.37bn₹69.67bn₹47.70bn₹33.64bn
Shareholders' equity₹378.91bn₹326.53bn₹298.43bn₹268.40bn₹245.76bn₹219.30bn₹168.25bn₹138.91bn₹116.80bn₹93.72bn
Shares outstanding578m581m581m584m586m586m586m586m586m586m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations₹55.13bn₹39.25bn₹24.35bn₹23.87bn₹50.16bn₹33.29bn₹43.81bn₹16.51bn₹19.55bn₹32.79bn
Capital spending−₹26.86bn−₹19.68bn−₹35.62bn−₹27.20bn−₹27.05bn−₹18.74bn−₹14.31bn−₹15.59bn−₹15.30bn−₹16.94bn
Free cash flow₹28.27bn₹19.57bn−₹11.27bn−₹3.34bn₹23.12bn₹14.55bn₹29.50bn₹918.7m₹4.25bn₹15.84bn
Dividends paid−₹2.32bn−₹10.4m−₹2.64bn−₹4.40bn−₹2.64bn−₹2.34bn−₹1.76bn−₹1.46bn−₹2.19bn−₹1.14bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₹91.06bn₹88.53bn₹86.46bn₹82.86bn₹78.68bn₹83.82bn₹79.79bn₹77.96bn
Operating income₹13.94bn₹13.22bn₹14.01bn₹12.49bn₹34.00bn₹15.71bn₹35.32bn₹34.76bn
Net income₹10.33bn₹9.21bn₹9.10bn₹8.48bn₹8.25bn₹9.03bn₹8.46bn₹8.17bn
Diluted earnings per share17.8615.9315.6714.6114.2015.5614.5614.07
Cash from operations———₹28.85bn—₹39.25bn—₹6.53bn
Capital spending———−₹13.63bn—−₹25.20bn—−₹8.80bn
Free cash flow———₹15.22bn—₹14.06bn—−₹2.27bn
Total assets—₹585.02bn—₹525.46bn—₹497.85bn—₹480.94bn
Cash and short-term investments₹105.85bn₹106.18bn₹88.92bn₹88.92bn₹82.36bn₹82.36bn₹68.68bn₹68.68bn
Debt—₹77.80bn—₹77.94bn—₹82.63bn—₹84.27bn
Shareholders' equity₹378.83bn₹378.91bn₹350.34bn₹350.41bn₹326.47bn₹326.53bn₹308.85bn₹308.78bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue10.6%6.3%9.3%
Operating income-12.1%-10.2%-0.2%
Net income22.1%-8.1%5.6%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin16.9%20.0%24.5%29.4%
Net margin10.7%10.1%12.0%12.5%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings28.419.724.432.89.78.018.911.317.717.5
Price to sales3.02.22.72.51.11.72.31.42.62.7

Dividends and splits

Per share, in the currency the company pays

Paid for 31 years. Last went ex-dividend on 8 Aug 2025.

FY2026FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Paid in the year4.004.507.504.504.003.002.503.75
  • 2-for-1 split · 20 Jul 2015
  • 5-for-1 split · 10 Feb 2011
  • 2-for-1 split · 23 Oct 2003
  • 2-for-1 split · 7 Mar 2000
  • 2-for-1 split · 26 Oct 1998

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.